Abstract:Active tuberculosis (aTB) remains a major killer from infectious disease, partially due to delayed diagnosis and hence treatment. Classical microbiological methods are slow and lack sensitivity, molecular techniques are costly and often unavailable. Moreover, available immuno-diagnostic tests lack sensitivity and do not differentiate between aTB and latent TB infection (LTBI). Here, we evaluated the performance of the combined measurement of different chemokines/cytokines induced by two different stage-specific mycobacterial antigens, Early-secreted-antigenic target-6 (ESAT-6) and Heparin-binding-haemagglutinin (HBHA), after a short in vitro incubation of either peripheral blood mononuclear cells (PBMC) or whole blood (WB). Blood samples were collected from a training cohort comprising 22 aTB patients, 22 LTBI subjects and 17 non-infected controls. The concentrations of 13 cytokines were measured in the supernatants. Random forest analysis identified the best markers to differentiate M. tuberculosis-infected from non-infected subjects, and the most appropriate markers to differentiate aTB from LTBI. Logistic regression defined predictive abilities of selected combinations of cytokines, first on the training and then on a validation cohort (17 aTB, 27 LTBI, 25 controls). Combining HBHA- and ESAT-6-induced IFN-γ concentrations produced by PBMC was optimal to differentiate infected from non-infected individuals in the training cohort (100% correct classification), but 2/16 (13%) patients with aTB were misclassified in the validation cohort. ESAT-6-induced-IP-10 combined with HBHA-induced-IFN-γ concentrations was selected to differentiate aTB from LTBI, and correctly classified 82%/77% of infected subjects as aTB or LTBI in the training/validation cohorts, respectively. Results obtained on WB also selected ESAT-6- and HBHA-induced IFN-γ concentrations to provided discrimination between infected and non-infected subjects (89%/90% correct classification in the training/validation cohorts). Further identification of aTB patients among infected subjects was best achieved by combining ESAT-6-induced IP-10 with HBHA-induced IL-2 and GM-CSF. Among infected subjects, 90%/93% of the aTB patients were correctly identified in the training/validation cohorts. We therefore propose a two steps strategy performed on 1 mL WB for a rapid identification of patients with aTB. After elimination of most non-infected subjects by combining ESAT-6 and HBHA-induced IFN-γ, the combination of IP-10, IL-2 and GM-CSF released by either ESAT-6 or HBHA correctly identifies most patients with aTB.

Antigen-specific chemokine profiles as biomarkers for detecting Mycobacterium tuberculosis infection

Multiplex Analysis of Plasma Cytokines/chemokines Showing Different Immune Responses in Active TB Patients, Latent TB Infection and Healthy Participants.

Characterization of cytokine profile to distinguish latent tuberculosis from active tuberculosis and healthy controls.

Specific Cytokines Analysis Incorporating Latency-Associated Antigens Differentiates Mycobacterium tuberculosis Infection Status: An Exploratory Study

Diagnostic Performance of a Novel CXCL10 mRNA Release Assay for Mycobacterium tuberculosis Infection

Evaluation of the Diagnostic Potential of IP-10 and IL-2 As Biomarkers for the Diagnosis of Active and Latent Tuberculosis in a BCG-Vaccinated Population

Analysis Of Plasma Cytokine And Chemokine Profiles In Patients With And Without Tuberculosis By Liquid Array-Based Multiplexed Immunoassays

Screening and identification of a six-cytokine biosignature for detecting TB infection and discriminating active from latent TB

Diagnostic Performance of Multiplex Cytokine and Chemokine Assay for Tuberculosis.

The Association Between Mycobacteria-Specific Antigen-Induced Cytokines and Host Response to Latent Tuberculosis Infection Treatment in a Chinese Population

The meta-analysis for ideal cytokines to distinguish the latent and active TB infection

The potential value of mtb-specific-antiqen induced factors as biomarkers for the differential diagnosis of active pulmonary tuberculosis

Immuno-Diagnosis of Active Tuberculosis by a Combination of Cytokines/Chemokines Induced by Two Stage-Specific Mycobacterial Antigens: A Pilot Study in a Low TB Incidence Country

Combined analysis of host IFN-γ, IL-2 and IP-10 as potential LTBI biomarkers in ESAT-6/CFP-10 stimulated blood

Multiple cytokine responses in discriminating between active tuberculosis and latent tuberculosis infection

Potential Role for Mycobacterium Tuberculosis Specific IL-2 and IFN-γ Responses in Discriminating Between Latent Infection and Active Disease after Long-Term Stimulation

Evaluation of Gamma Interferon Release Assays Using Mycobacterium Tuberculosis Antigens for Diagnosis of Latent and Active Tuberculosis in Mycobacterium Bovis Bcg-Vaccinated Populations

Profiling the human immune response to Mycobacterium tuberculosis by human cytokine array

Novel Biomarkers Distinguishing Active Tuberculosis From Latent Infection Identified By Gene Expression Profile Of Peripheral Blood Mononuclear Cells

IL-6 Release of Rv0183 Antigen-Stimulated Whole Blood is a Potential Biomarker for Active Tuberculosis Patients.

Genome-wide Transcriptional Profiling Identifies Potential Signatures in Discriminating Active Tuberculosis from Latent Infection